Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition
On December 27, the 12th Conference of the Chinese Pharmacopoeia Commission (ChPC) Executive Committee concluded...
Huadong Medicine’s Arcalyst Receives NMPA Approval for Cryopyrin-Associated Periodic Syndromes
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing approval from the National...
Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval...
MicuRx Pharmaceuticals’ MRX-4 Combo Shows Positive Results in Phase III Study
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced positive results from a Phase III...
National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs
The National Medical Products Administration has released the finalized National Reimbursement Drug List (NRDL) for...
Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs
Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs)...
China’s NHC Aims to Enhance Continuity of Medical Services with Referral System by 2030
The National Health Commission (NHC) has released a notification aimed at enhancing the continuity of...
Jiangsu Kanion Pharmaceutical Secures NMPA Approvals for KYHY2302 and KYHY2303
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving separate clinical trial approvals...
NHSA Issues Guidelines to Suspend Direct Online Listing of In-Shortage Drugs
The National Healthcare Security Administration (NHSA) has issued the “Guidelines for Risk Management of In-Shortage...
BeiGene’s Tevimbra Receives EC Approval for First-Line ESCC and G/GEJ Adenocarcinoma Treatments
China-based biotech company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has received a marketing...
Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Cervical Muscle Tone Disorders
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Phil Rivers Technology Secures IND Approval for PR00012 from NMPA’s CDE
Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing...
Hansoh Pharmaceutical’s Ameile Receives NMPA Review for Fifth Indication in NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that its fifth indication filing...
China Medical System Holdings Gets NMPA Approval to Test Obesity Treatment CMS-D005
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval...
Genesis RMN Robotic Magnetic Navigation System Approved by China’s NMPA
The Genesis RMN cardiac electrophysiological robot magnetic navigation system, represented in China by Shanghai Microport...
GSK plc Receives EC Approval for Single-Vial Menveo Vaccine for Meningococcal Disease
GSK plc (NYSE: GSK) has announced that it has received marketing approval from the European...
TenNor Therapeutics Partners with Grand Life Sciences for Rifasutenizol Commercialization in China
China-based TenNor Therapeutics has entered into an exclusive commercialization cooperation agreement with compatriot firm Grand...
Immunochina Pharmaceuticals’ IM19 CAR-T Therapy Accepted for Review by NMPA
Beijing-based biotech company Immunochina Pharmaceuticals has announced that the National Medical Products Administration (NMPA) has...
Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment
China-based Thederma has announced that its TAP-1503 cream has been granted approval by the National...
Novartis’s Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced that it has received marketing approval from...